| Laura Dorrian, | |
|
7 Bayberry Dr, Suffern, NY 10901-4301 | |
| (845) 369-6253 | |
| Not Available |
| Full Name | Laura Dorrian |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 7 Bayberry Dr, Suffern, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730518945 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | 3120081 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Laura Dorrian, 7 Bayberry Dr, Suffern, NY 10901 Ph: (845) 369-6253 | Laura Dorrian, 7 Bayberry Dr, Suffern, NY 10901-4301 Ph: (845) 369-6253 |
News Archive
New international guidelines published in the journal Transplantation reinforce the use of a new type of blood test to assess cytomegalovirus (CMV) risk in solid organ transplant recipients (i.e. transplant recipients). This blood test, QuantiFERON®-CMV (QF-CMV), is the first commercially-available blood test to allow physicians to monitor a person's risk of CMV disease. Most commonly used in the transplant setting, QF-CMV may predict which transplant recipients are at increased risk of CMV disease after transplant surgery.
Recent scientific findings have raised the fear that young athletes may fare worse after sustaining a sports-related concussion than older athletes.
When you take a medication for, say, high cholesterol, do you know that pill is really what the label says it is? Depending upon the type of medicine and where you live, the threat of falsified medications (also referred to as counterfeit, fraudulent, and substandard) can be quite real, yet the full scope and prevalence of the problem is poorly understood, say researchers at University of California, San Diego School of Medicine in a new report published April 20 in the American Journal of Tropical Medicine and Hygiene.
Inhibitex, Inc., today announced its financial results for the third quarter ended September 30, 2009. The Company held cash, cash equivalents and short-term investments of $21.1 million at September 30, 2009, as compared to $33.1 million at December 31, 2008.
We talked to Kayte from Trajan Medical and Scientific Technologies at Trajan.
› Verified 7 days ago